Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess

Galderma shares slid the most in over a year after the FDA turned down its rival Botox treatment Relfydess. The US regulatory setback raises near-term commercial and competitive uncertainty for the product, pressuring sentiment toward Galderma’s dermatology pipeline.

Analysis

Galderma shares slid the most in over a year after the FDA turned down its rival Botox treatment Relfydess. The US regulatory setback raises near-term commercial and competitive uncertainty for the product, pressuring sentiment toward Galderma’s dermatology pipeline.